CSL share price 'ticks all the defensive boxes': fundie

CSL's plasma business operates one of the largest plasma collection networks in the world.

| More on:
Two happy scientists analysing test results.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price is up 1.4% in early afternoon trade at $304.58 per share.

The global biotechnology company is outpacing the S&P/ASX 200 Index (ASX: XJO) today, with the benchmark index having only just clawed its way back into the green, up 0.1%.

That's today's price action for you.

Now, here's why this fund manager is bullish on the CSL share price moving forward.

A defensive ASX 200 share in volatile times

Speaking to Livewire, Blake Henricks, portfolio manager at Firetrail Investments said CSL fits the bill as a defensive ASX 200 share likely to remain resilient despite any future market volatility.

"It's large, it's liquid, it's healthcare. So to me, it ticks all the defensive boxes. It's in a defensive growth category," he said.

CSL's plasma business operates one of the largest plasma collection networks in the world.

Which is a core reason why Henricks sees growth ahead for the CSL share price:

I think what's really important is, the tougher the economy gets, the lower one of their key costs goes. And that's the plasma collection. This is where they pay donors to give blood and they turn that into plasma. The higher unemployment goes, the more people want to give plasma and the costs come down. On that basis, it's really attractive as a defensive. 

Henricks acknowledged that some investors may be put off by the high price-to-earnings (P/E) ratio. At the current CSL share price, that's just over 40 times.

But that P/E ratio is backwards looking. Meaning it's based on CSL's share price today and on its earnings over the past financial year.

Henricks believes those earnings are set to increase, bringing the P/E ratio sharply lower:

2023 is already written. 2024, the earnings are looking very strong in our view, and you're seeing it in a mid to high-20s P/E. They expense all their R&D. It's a very well-run business. And for a defensive, I can't go past it.

How has the CSL share price performed longer-term?

Over the past five years, the CSL share price has gained 109%, compared to a 21% gain posted by the ASX 200 over that same period.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Up 427% this year, why today is a big day for Mesoblast shares

Why is everyone talking about Mesoblast shares on Friday?

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Is this beaten-down ASX healthcare share a bargain buy now?

One expert has given their view on this stock.

Read more »

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

Buy this ASX 200 share that is swimming in cash

Bell Potter sees potentially big returns on offer from this cashed-up stock.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »